<SEC-DOCUMENT>0001144204-18-011743.txt : 20180228
<SEC-HEADER>0001144204-18-011743.hdr.sgml : 20180228
<ACCEPTANCE-DATETIME>20180228160248
ACCESSION NUMBER:		0001144204-18-011743
CONFORMED SUBMISSION TYPE:	F-1/A
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20180228
DATE AS OF CHANGE:		20180228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3

	FILING VALUES:
		FORM TYPE:		F-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-208817
		FILM NUMBER:		18651055

	BUSINESS ADDRESS:	
		STREET 1:		XTL BIOPHARMACEUTICALS LTD
		STREET 2:		C/O ALSTON & BIRD LLP, 90 PARK AVENUE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		972 9 955 7080

	MAIL ADDRESS:	
		STREET 1:		5 HACHAROSHET ST.
		CITY:			RAANANA
		STATE:			L3
		ZIP:			4365603
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-1/A
<SEQUENCE>1
<FILENAME>tv487224_f1-a.htm
<DESCRIPTION>F-1/A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>As filed with the Securities and Exchange
Commission on February 28, 2018.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No. 333-208817</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND
EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">WASHINGTON, D.C.
20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Amendment No.
3 to</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM F-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>XTL Biopharmaceuticals
Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>(Exact name of
registrant as specified in its charter)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Israel</B></FONT></TD>
    <TD STYLE="width: 34%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2834</B></FONT></TD>
    <TD STYLE="width: 33%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Not
    Applicable</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(State or other jurisdiction
        of</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>incorporation or organization)</I></P></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Primary Standard Industrial</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Classification Code Number)</I></P></TD>
    <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(I.R.S.
    Employer Identification No.)</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>5 Badner St.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ramat Gan, Israel, 5218102</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Tel: (972) 3-6116600</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Address, including zip code, and telephone
number, including area code, of registrant&rsquo;s principal executive offices)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>c/o Corporation Trust Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Corporation Trust Center</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1209 N. Orange Street</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Wilmington, DE 19801</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(800) 677-3394</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Name, Address, including zip code,
and telephone number, including area code, of agent for service)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Copies of all correspondence to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 50%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Gregory
    Sichenzia, Esq.</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 50%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ronen
    Kantor, Adv.&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Avital Perlman,
    Esq.</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ron Soulema, Adv.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sichenzia Ross
    Ference Kesner LLP</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Doron Tikotzky
    Kantor Gutman &amp; Amit Gross.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1185 Avenue of
    the Americas</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7 Metsada St.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>New York, NY 10036</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Bnei Brak, Israel
    5126112</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tel: (212) 930-9700</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tel: (972) 3-6133371</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fax: (212) 930-9725</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fax: (972) 3-6133372</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Approximate date of commencement of proposed sale to the
public:</B> From time to time after this Registration Statement becomes effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under
the Securities Act of 1933, check the following box.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the
same offering.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333">Indicate by check
mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right; background-color: white; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif">Emerging
growth company </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards&dagger;
provided pursuant to Section 7(a)(2)(B) of the Securities Act. </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333">&dagger; The term
&ldquo;new or revised financial accounting standard&rdquo; refers to any update issued by the Financial Accounting Standards Board
to its Accounting Standards Codification after April 5, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXPLANATORY NOTE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">XTL Biopharmaceuticals
Ltd. (the &ldquo;Registrant&rdquo;) is filing this Amendment No. 3 (the &ldquo;Amendment&rdquo;) to its Registration Statement
on Form F-1 (Registration Statement No. 333-208817) (the &ldquo;Registration Statement&rdquo;) to file Exhibit 5.1. Accordingly,
this Amendment consists only of the facing page, this explanatory note, Item 8 of Part II of the Registration Statement, the signature
page, the Exhibit Index and Exhibit 5.1. The remainder of the Registration Statement is unchanged and therefore has not been included
in this Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 8. Exhibits and Financial Statement Schedules</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Exhibits</I></B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify">See Exhibit Index.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.65pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The agreements included
as exhibits to this registration statement contain representations and warranties by each of the parties to the applicable agreement.
These representations and warranties were made solely for the benefit of the other parties to the applicable agreement and (i)
were not intended to be treated as categorical statements of fact, but rather as a way of allocating the risk to one of the parties
if those statements prove to be inaccurate; (ii) may have been qualified in such agreement by disclosures that were made to the
other party in connection with the negotiation of the applicable agreement; (iii) may apply contract standards of &ldquo;materiality&rdquo;
that are different from &ldquo;materiality&rdquo; under the applicable securities laws; and (iv) were made only as of the date
of the applicable agreement or such other date or dates as may be specified in the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Registrant acknowledges
that, notwithstanding the inclusion of the foregoing cautionary statements, the registrant is responsible for considering whether
additional specific disclosures of material information regarding material contractual provisions are required to make the statements
in this registration statement not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Financial
    Statement Schedules</I></B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All schedules have
been omitted because either they are not required, are not applicable or the information is otherwise set forth in the consolidated
financial statements and related notes thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 39.65pt">Pursuant to the
requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form F-1 and has duly caused this registration statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of Ramat Gan, State of Israel on this 28th day of February 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>XTL
    Biopharmaceuticals Ltd.</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 30%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Joshua Levine</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joshua Levine</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-left: 19.8pt; text-align: justify; text-indent: -19.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 39.65pt">Pursuant to the
requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons in the
capacities and on the dates indicated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 9.9pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 9.9pt">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer </FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Joshua Levine </FONT></TD>
    <TD STYLE="vertical-align: top; padding-left: 9.9pt">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(principal executive officer) </FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    28, 2018 </FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joshua
    Levine </FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 9.9pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Itay Weinstein </FONT></TD>
    <TD STYLE="vertical-align: top; padding-left: 9.9pt">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer </FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Itay
    Weinstein </FONT></TD>
    <TD STYLE="vertical-align: top; padding-left: 9.9pt">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(principal financial officer and principal </FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 9.9pt">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">accounting officer) </FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    28, 2018 </FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 9.9pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    * </FONT></TD>
    <TD STYLE="vertical-align: top; padding-left: 9.9pt">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board </FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shlomo
    Shalev </FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    28, 2018 </FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 9.9pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-left: 9.9pt">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director </FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alexander
    Rabinovich </FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    28, 2018 </FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 9.9pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    * </FONT></TD>
    <TD STYLE="vertical-align: top; padding-left: 9.9pt">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director </FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Osnat
    Hillel Fain </FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    28, 2018 </FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 9.9pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    * </FONT></TD>
    <TD STYLE="vertical-align: top; padding-left: 9.9pt">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director </FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oded
    Nagar </FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    28, 2018 </FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 9.9pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    * </FONT></TD>
    <TD STYLE="vertical-align: top; padding-left: 9.9pt">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director </FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jonathan
    Schapiro </FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    28, 2018 </FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    * </FONT></TD>
    <TD STYLE="vertical-align: top; padding-left: 9.9pt">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director </FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dobroslav
    Melamed </FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    28, 2018 </FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 9.9pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    * </FONT></TD>
    <TD STYLE="vertical-align: top; padding-left: 9.9pt">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director </FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Doron
    Turgeman </FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    28, 2018 </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">* By executing his name hereto, Joshua
Levine is signing this document on behalf of the persons indicated above pursuant to the powers of attorney duly executed by such
persons and filed with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="width: 30%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Joshua Levine </FONT></TD>
    <TD STYLE="width: 65%">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joshua Levine </FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 28, 2018 </FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><B>SIGNATURE
OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Pursuant
to the Securities Act of 1933, the undersigned, as the duly authorized representative of XTL Biopharmaceuticals Ltd. in the United
States, signed this registration statement on February 28, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XTL Biopharmaceuticals Ltd.</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Joshua
    Levine</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Joshua Levine</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 8%"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420405024363/v022798_20fr12ga.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></A></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 91%"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420405024363/v022798_20fr12ga.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Articles
    of Association (9)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420407014214/v068912_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420407014214/v068912_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Share Certificate (including both Hebrew and English translations) (2)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000101915507000345/xtlexdepagmt83105.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000101915507000345/xtlexdepagmt83105.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of American Depositary Receipt (included in Exhibit 10.1)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="tv487224_ex5-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1
    </FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="tv487224_ex5-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion
    of Doron Tikotzky Kantor Gutman &amp; Amit Gross., Israeli counsel to the Registrant* </FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000101915507000345/xtlexdepagmt83105.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000101915507000345/xtlexdepagmt83105.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deposit
    Agreement, dated as of August 31, 2005, by and between XTL Biopharmaceuticals Ltd., The Bank of New York, as Depositary, and
    each holder and beneficial owner of American Depositary Shares issued thereunder (1)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000101915507000345/xtlexdepagmt83105.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000101915507000345/xtlexdepagmt83105.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2001
    Share Option Plan dated February 28, 2001 (1)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420415073635/v427869_ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420415073635/v427869_ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2011
    Share Option Plan dated August 29, 2011 (6)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420409019131/v145414_ex10-44.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420409019131/v145414_ex10-44.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and License Agreement Between Yeda Research and Development Company Ltd., Mor Research Applications Ltd., Biogal Ltd. (under
    its previous name Haverfield Ltd.) and Biogal Advanced Biotechnology Ltd. dated January 7, 2002 (3) &dagger;</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420409019131/v145414_ex10-45.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420409019131/v145414_ex10-45.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment
    to Research and License Agreement Between Yeda Research and Development Company Ltd., Mor Research Applications Ltd., Haverfield
    Ltd. and Biogal Advanced Biotechnology Ltd. effective as of April 1, 2008 (3) &dagger;</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420411033048/v224319_ex10-52.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420411033048/v224319_ex10-52.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option
    to License Agreement, dated as of September 1, 2010, between XTL Biopharmaceuticals Ltd. and Yeda Research and Development
    Company Limited (4)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420414020261/v373623_ex10-13.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420414020261/v373623_ex10-13.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">License
    Agreement dated January 7, 2014, by and between Yeda Research and Development Company Limited and XTL Biopharmaceuticals Ltd
    (5)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420415073635/v427869_ex10-8.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420415073635/v427869_ex10-8.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of First Amendment to License Agreement by and by and between Yeda Research and Development Company Limited and XTL Biopharmaceuticals
    Ltd. (6)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420415073635/v427869_ex10-9.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420415073635/v427869_ex10-9.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Employment Agreement dated September 11, 2013 between XTL Biopharmaceuticals Ltd. and Joshua Levine (6)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420415073635/v427869_ex10-10.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420415073635/v427869_ex10-10.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Employment Agreement dated January 9, 2014 between XTL Biopharmaceuticals Ltd. and David Kestenbaum (6)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420415073635/v427869_ex10-11.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420415073635/v427869_ex10-11.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Consulting Agreement dated January 1, 2015 between XTL Biopharmaceuticals Ltd. and Schapiro Education Ltd. (6)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420418005222/tv484585_ex10-12.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420418005222/tv484585_ex10-12.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Employment Agreement dated June 11, 2017 between XTL Biopharmaceuticals Ltd. and Joshua Levine (10)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420417010284/v460062_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420417010284/v460062_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Letter
    Agreement between Rodman &amp; Renshaw, a unit of H.C. Wainwright &amp; Co., LLC, and XTL Biopharmaceuticals Ltd. dated November
    7, 2016 (7)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420417010284/v460062_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420417010284/v460062_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment
    to Letter Agreement between Rodman &amp; Renshaw, a unit of H.C. Wainwright &amp; Co., LLC, and XTL Biopharmaceuticals Ltd.
    dated February 16, 2017&nbsp;&nbsp;(7)</FONT></A></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 8%"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420417010284/v460062_ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</FONT></A></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 91%"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420417010284/v460062_ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Securities Purchase Agreement dated February 17, 2017 (7)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420417010284/v460062_ex10-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420417010284/v460062_ex10-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Warrant issued February 21, 2017(7)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420417013699/v461517_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420417013699/v461517_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Securities Purchase Agreement dated March 7, 2017 (8)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420417013699/v461517_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420417013699/v461517_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Warrant issued March 10, 2017(8)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420415073635/v427869_ex21-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420415073635/v427869_ex21-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">List
    of Subsidiaries (6)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420418005222/tv484585_ex23-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420418005222/tv484585_ex23-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Consent
    of Kesselman &amp; Kesselman, a member firm of PricewaterhouseCoopers International Ltd (10)</U></FONT></A></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; text-align: justify"><A HREF="tv487224_ex5-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</FONT></A></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 91%; text-align: justify"><A HREF="tv487224_ex5-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Doron Tikotzky      Kantor Gutman &amp; Amit Gross (included in Exhibit 5.1)*</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420415073635/v427869_f1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1023549/000114420415073635/v427869_f1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power
    of Attorney (6)</FONT></A></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">* </FONT></TD>
    <TD STYLE="text-align: justify; width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&dagger;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain confidential
    information contained in this exhibit was omitted.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify; width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference from the registration statement on F-6 filed with the Securities and Exchange Commission on November 28, 2007,
    as it may be amended or restated.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by
    reference from the annual report on Form 20-F filed by XTL Biopharmaceuticals Ltd. with the Securities and Exchange Commission
    on March 23, 2007 </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by
    reference from the annual report on Form 20-F filed by XTL Biopharmaceuticals Ltd. with the Securities and Exchange Commission
    on April 6, 2009.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by
    reference from the annual report on Form 20-F filed by XTL Biopharmaceuticals Ltd. with the Securities and Exchange Commission
    on May 30, 2011 </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by
    reference from the annual report on Form 20-F filed by XTL Biopharmaceuticals Ltd. with the Securities and Exchange Commission
    on April 2, 2014 </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by
    reference from the registration statement on F-1 filed with the Securities and Exchange Commission on December 31, 2015 </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by
    reference from the current report on Form 6-K filed by XTL Biopharmaceuticals Ltd. with the Securities and Exchange Commission
    on February 22, 2017 </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by
    reference from the current report on Form 6-K filed by XTL Biopharmaceuticals Ltd. with the Securities and Exchange Commission
    on March 9, 2017 </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by
    reference from the registration statement on Form 20-F filed with the Securities and Exchange Commission on August 10, 2005
    </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by
    reference from the registration statement on Form F-1 filed with the Securities and Exchange Commission on February 1, 2018</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>tv487224_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; padding-right: 0; padding-bottom: 0; padding-left: 0; font-size: 10pt; text-indent: 0"><IMG SRC="dtk.jpg" ALT=""></TD>
    <TD STYLE="width: 40%; padding-right: 0; padding-left: 0; padding-bottom: 0; text-indent: 0; text-align: right; vertical-align: bottom"><P STYLE="margin: 0pt 0">February
                                         28, 2018</P></TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">XTL Biopharmaceuticals Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5 Badner St.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ramat Gan 5218102</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">Dear Sir and Madam:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have acted as Israeli
counsel to XTL Biopharmaceuticals Ltd. (the &ldquo;Company&rdquo;), a company organized under the laws of the State of Israel.
As such, we have participated in the preparation of the Company&rsquo;s registration statement on Form F-1(the &ldquo;Registration
Statement&rdquo;) relating to the registration under the United States Securities Act of 1933, as amended (the &ldquo;Securities
Act&rdquo;), of the offering for resale by the selling shareholders therein of up to an aggregate to 385,000,000 ordinary shares,
par value NIS 0.1 per share of the Company (the &ldquo;Ordinary Shares&rdquo;) consisting of (i) 140,000,000 Ordinary Shares represented
by 1,400,000 unregistered ADSs originally issued to investors in a private placement in March 2017 (the &ldquo;March 2017 Ordinary
Shares&rdquo;); (ii) 140,000,000 Ordinary Shares (the &ldquo;March 2017 Warrant Shares&rdquo;) represented by 1,400,000 ADSs issuable
upon exercise of unregistered warrants originally issued to investors in a private placement in March 2017 (the &ldquo;March 2017
Warrants&rdquo;); (iii) 100,000,000 Ordinary Shares (the &ldquo;February 2017 Warrant Shares&rdquo;) represented by 1,000,000
ADSs issuable upon exercise of unregistered warrants originally issued to investors in a private placement in February 2017 (the
&ldquo;February 2017 Warrants&rdquo;) and (iv) 5,000,000 Ordinary Shares (the &ldquo;Placement Agent Warrant Shares&rdquo;) represented
by 50,000 ADSs issuable upon exercise of warrants issued to the placement agent and its affiliates in connection with the February
2017 private placement (the &ldquo;Placement Agent Warrants&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.5in">As counsel
to the Company in Israel, we have examined copies of the Articles of Association, as amended, of the Company and such corporate
records, instruments, and other documents relating to the Company and such matters of law as we have considered necessary or appropriate
for the purpose of rendering this opinion. In such examination, we have assumed the genuineness of all signatures, the authenticity
of all documents submitted to us as originals, and the conformity to authentic originals of all documents submitted to us as copies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the foregoing,
and subject to the assumption, limitation and qualifications set forth herein, we are of the opinion that the March 2017 Ordinary
Shares are duly authorized, legally issued, fully paid and non-assessable, and that the March 2017 Warrant Shares, the February
2017 Warrant Shares and the Placement Agent Warrant Shares underlying the March 2017 Warrants, the February 2017 Warrants and
the Placement Agent Warrants, respectively, when paid up for and issued pursuant to the terms of the applicable warrants, will
be dully authorized, legally issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.5in">We are members
of the Israeli bar, and the opinions expressed herein are limited to questions arising under the laws of the State of Israel,
and we disclaim any opinion whatsoever with respect to matters governed by the laws of any other jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We consent to the
filing of this opinion as an exhibit to the Registration Statement and to the use of our name in the Registration Statement under
the caption &ldquo;Legal Matters&rdquo; in the prospectus included in the Registration Statement. In giving such consent, we do
not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the
rules and regulations of the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">Very truly yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><U>/s/ Doron, Tikotzky,
Kantor, Gutman &amp; Gross</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">Doron, Tikotzky,
Kantor, Gutman &amp; Gross</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>dtk.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 dtk.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !L /,# 2(  A$! Q$!_\0
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M?\%>/A-^TQK>HVTOP2^)'PZ?P(WBN ^?INC7371O;6::5,JD,X9%63[OWR2
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M=?R6?\$F?^4FGP)_[';3/_2A*_K3KZCQB_W^A_@?_I3-L?\ $CY5\>?L5?\
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M]&^"OPZUGQI\$?B5\7/#'QLT:SDU"Q\1W_BF:_\ [>N8E+B#4(I 8I8I2-K
M( -P)5@"K?,?[;WCZ']N#_@A@/VOGU3QCX9^+-AI6G:+.-%\17EAIBSQ:Y'8
MW$@M(Y/+_>"25QG) D09^45-#+(5Y1]E6;BY*-[:J3VTOL]=;WTV!4U)Z,_6
MGX0?LG?"W]GO4KJ\\!?#;P'X*O+U2EQ/H6@6NG2SJ2#M9H8U)&0."<<"NKN_
M ^BW_BRTU^?1]+FUVPA:WMM1DM(VN[>)OO(DI&]5.>0#@U\M_"/_ ()0_#*V
M_9VN]!.L_%&2S\;0Z7J6I32^.-2>Y26W21T\F4R[XE)GDW*A ?"YSM%?,_\
MP1[_ &8-'^+W[;?Q'^,WA/7/'DWP4\!W\GA;P);:MXHOM3A\17L:&.]U1O.D
M8/$"Q6'^'Y\X#QYK'ZK3J0JUO:M\G5K>^B5^;J[_ "39/*FF[GZC:YH-EXGT
MF>PU*SMK^QN5VS6]Q$LL4HZX96!!Y _*K=?BA^R=^UE\1OVRI+C]DCX?>+=3
M\/ZQJ7BGQ/K'Q \8W-V?M^D: -5EC%IIQD.YIY%95WID1*ZXZ.4^DOVHDN/^
M"*WQU^'_ ,6=$OO%&H_L_:W9VW@GXA:;>7T^J2:1,@;[#K*>8S/YC,S),W\6
M0,%Y%QK5R.=.I]7E/WW=Q5M^WHY?9773NANBT^6^I^CM%?'/_!)[1O'GQPT_
MQ-^TA\2Y]6L=7^,11_#'AF6X;[)X7\.1DFRC6+.WSYU/G228RP9#\N6%?8U>
M3BJ'L:KI7NUOZ]5\GI<RDK.P4445SB"BBB@ HHHH _,7XQ?\IL+/_L8=(_\
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M?A;X7\0L+G5?B1KD-C)&LF/[)T\N(Y;^7J=BNR #^+$F/N&OIVOP!_X.VO\
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M"Y(&3QDBOUO(?"O#4Z"Q.=3UW<4[)?XG^=K6[L^UIX*-KU#ZD_;1_;H^)?\
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M&KVN#-9:A:O;SQ@C()1P#@CD'N*_;^(>#<!G56'UVK+VL8Z<KBM+[\K3TO\
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M K/,,PH5<'&C2TDE&^^MDU;LN5M]-4_(*E2+A9>1[I1117S9SA1110 4444
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MP2^(W@?]LCX6ZH_@CQC9P6WBK3?M$\VC7,<<4+7,:2%F* *NQFR3P!7Z?_\
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M.MKK[2:Z'Z:?\&X?@*SNM>^*7B>6%6OK*"PTRVE(YCCE:>24#ZF*'_OFM_\
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MV^Z2(K!L4L^]F;=MQ@9S7BW_  2LU2"Q_P""HO[=FCS2+%J9\5:+?K;N<2/
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'**^<,#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
